Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dyslipidemia

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    May 2016
  1. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


  2. ZHOU T, Ding JW, Wang XA, Zheng XX, et al
    Long noncoding RNAs and atherosclerosis.
    Atherosclerosis. 2016;248:51-61.
    PubMed     Text format     Abstract available


  3. PAN L, Yang Z, Wu Y, Yin RX, et al
    The prevalence, awareness, treatment and control of dyslipidemia among adults in China.
    Atherosclerosis. 2016;248:2-9.
    PubMed     Text format     Abstract available


    April 2016
  4. HUANG Y, Xu M, Xie L, Wang T, et al
    Obesity and peripheral arterial disease: A Mendelian Randomization analysis.
    Atherosclerosis. 2016;247:218-24.
    PubMed     Text format     Abstract available


  5. KOLODZIEJCZAK M, Navarese EP
    Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Atherosclerosis. 2016;247:189-92.
    PubMed     Text format     Abstract available


    March 2016
  6. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Text format     Abstract available


  7. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Text format     Abstract available


  8. ROTLLAN N, Price N, Pati P, Goedeke L, et al
    microRNAs in lipoprotein metabolism and cardiometabolic disorders.
    Atherosclerosis. 2016;246:352-60.
    PubMed     Text format     Abstract available


  9. EL TAHLAWI M, Sakrana A, Elmurr A, Gouda M, et al
    The relation between coronary tortuosity and calcium score in patients with chronic stable angina and normal coronaries by CT angiography.
    Atherosclerosis. 2016;246:334-7.
    PubMed     Text format     Abstract available


  10. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  11. PEDERSEN LR, Olsen RH, Anholm C, Walzem RL, et al
    Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
    Atherosclerosis. 2016;246:221-8.
    PubMed     Text format     Abstract available


  12. ESCATE R, Padro T, Badimon L
    LDL accelerates monocyte to macrophage differentiation: Effects on adhesion and anoikis.
    Atherosclerosis. 2016;246:177-86.
    PubMed     Text format     Abstract available


  13. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  14. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    February 2016
  15. AMOR AJ, Catalan M, Perez A, Herreras Z, et al
    Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
    Atherosclerosis. 2016;247:161-169.
    PubMed     Text format     Abstract available


  16. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Text format     Abstract available


  17. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Text format     Abstract available


    January 2016
  18. LATET SC, Van Craenenbroeck AH, Van Herck PL, Van Craenenbroeck EM, et al
    A critical view of monocyte subpopulations in human hypercholesterolemia.
    Atherosclerosis. 2016 Jan 14. pii: S0021-9150(16)30021.
    PubMed     Text format    


  19. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Text format     Abstract available


  20. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  21. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


    December 2015
  22. RASMUSSEN KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, et al
    Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
    Atherosclerosis. 2015;246:63-70.
    PubMed     Text format     Abstract available


  23. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Text format     Abstract available


  24. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Text format     Abstract available


    October 2015
  25. BASU A, Jenkins AJ, Zhang Y, Stoner JA, et al
    Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
    Atherosclerosis. 2015;244:93-100.
    PubMed     Text format     Abstract available


  26. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.
    PubMed     Text format    


  27. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Text format     Abstract available


    September 2015
  28. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Text format     Abstract available


  29. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.
    PubMed     Text format    


  30. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Text format     Abstract available


  31. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Text format     Abstract available


  32. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Text format     Abstract available


  33. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Text format     Abstract available


    August 2015
  34. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Text format     Abstract available


    July 2015
  35. BOS S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, et al
    Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Atherosclerosis. 2015;242:226-229.
    PubMed     Text format     Abstract available


  36. ISHIKAWA T, Ayaori M, Uto-Kondo H, Nakajima T, et al
    High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease.
    Atherosclerosis. 2015;242:318-322.
    PubMed     Text format     Abstract available


  37. PEREIRA C, Miname MH, Makdisse MR, Watanabe C, et al
    Peripheral arterial disease in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;242:174-178.
    PubMed     Text format     Abstract available


  38. STOCK J, Hayes C
    Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.
    Atherosclerosis. 2015;242:277-280.
    PubMed     Text format    


  39. GALEMA-BOERS JM, Versmissen J, Roeters van Lennep HW, Dusault-Wijkstra JE, et al
    Cascade screening of familial hypercholesterolemia must go on.
    Atherosclerosis. 2015;242:415-417.
    PubMed     Text format     Abstract available


  40. KOTUR-STEVULJEVIC J, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Stefanovic A, et al
    Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients.
    Atherosclerosis. 2015;241:192-8.
    PubMed     Text format     Abstract available


  41. TACHIKAWA R, Koyasu S, Matsumoto T, Hamada S, et al
    Obstructive sleep apnea and abdominal aortic calcification: Is there an association independent of comorbid risk factors?
    Atherosclerosis. 2015;241:6-11.
    PubMed     Text format     Abstract available


    June 2015
  42. BARRIOS C, Pascual J, Otero S, Soler MJ, et al
    Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Atherosclerosis. 2015;242:37-44.
    PubMed     Text format     Abstract available


  43. KWON M, Han SM, Kim DI, Rhee MY, et al
    Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;242:8-12.
    PubMed     Text format     Abstract available


  44. AHN HY, Kim M, Chae JS, Ahn YT, et al
    Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia.
    Atherosclerosis. 2015;241:649-656.
    PubMed     Text format     Abstract available


  45. MINICOCCI I, Prisco C, Montali A, Di Costanzo A, et al
    Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach.
    Atherosclerosis. 2015;242:618-624.
    PubMed     Text format     Abstract available


  46. ITO MK
    Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature.
    Atherosclerosis. 2015 Jun 11. pii: S0021-9150(15)01366.
    PubMed     Text format     Abstract available


  47. BESSELING J, Sjouke B, Kastelein JJ
    Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).
    Atherosclerosis. 2015;241:597-606.
    PubMed     Text format     Abstract available


  48. AUSCHER S, Heinsen L, Nieman K, Vinther KH, et al
    Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography.
    Atherosclerosis. 2015;241:579-587.
    PubMed     Text format     Abstract available


  49. BRAAMSKAMP MJ, Kusters DM, Wiegman A, Avis HJ, et al
    Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
    Atherosclerosis. 2015;241:427-432.
    PubMed     Text format     Abstract available


  50. THOMPSON GR
    Obituary of Dr N.B. Myant.
    Atherosclerosis. 2015;240:437-8.
    PubMed     Text format    


  51. ASAKAWA T, Hayashi T, Tanaka Y, Joki N, et al
    Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease.
    Atherosclerosis. 2015;240:535-43.
    PubMed     Text format     Abstract available


  52. GERARDS MC, Terlou RJ, Yu H, Koks CH, et al
    Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Atherosclerosis. 2015;240:415-23.
    PubMed     Text format     Abstract available


    May 2015
  53. MASANA L, Pedro-Botet J, Civeira F
    IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Atherosclerosis. 2015;240:161-2.
    PubMed     Text format    


  54. ZHANG T, Zhang C, Zhang Y, Tang F, et al
    Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Atherosclerosis. 2015;240:144-8.
    PubMed     Text format     Abstract available


  55. KOOPAL C, Retterstol K, Sjouke B, Hovingh GK, et al
    Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Atherosclerosis. 2015;240:90-7.
    PubMed     Text format     Abstract available


  56. RABACCHI C, Pisciotta L, Cefalu AB, Noto D, et al
    Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
    Atherosclerosis. 2015;241:79-86.
    PubMed     Text format     Abstract available


    April 2015
  57. DE BACKER G, Besseling J, Chapman J, Hovingh GK, et al
    Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
    Atherosclerosis. 2015;241:169-175.
    PubMed     Text format     Abstract available


  58. ODA E
    Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population.
    Atherosclerosis. 2015;241:1-5.
    PubMed     Text format     Abstract available


  59. WATTS GF, Pang J, Santos RD
    Europe aspires to set the record straight on familial hypercholesterolaemia.
    Atherosclerosis. 2015 Apr 20. pii: S0021-9150(15)00234.
    PubMed     Text format    


  60. UENO Y, Yamashiro K, Tanaka Y, Watanabe M, et al
    Rosuvastatin may stabilize atherosclerotic aortic plaque: transesophageal echocardiographic study in the EPISTEME trial.
    Atherosclerosis. 2015;239:476-82.
    PubMed     Text format     Abstract available


  61. NUOTIO J, Oikonen M, Magnussen CG, Viikari JS, et al
    Adult dyslipidemia prediction is improved by repeated measurements in childhood and young adulthood. The Cardiovascular Risk in Young Finns Study.
    Atherosclerosis. 2015;239:350-7.
    PubMed     Text format     Abstract available


    March 2015
  62. STEFANUTTI C, Blom DJ, Averna MR, Meagher EA, et al
    The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Atherosclerosis. 2015;240:408-414.
    PubMed     Text format     Abstract available


  63. GUARDIOLA M, Cofan M, de Castro-Oros I, Cenarro A, et al
    APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.
    Atherosclerosis. 2015;240:98-104.
    PubMed     Text format     Abstract available


  64. DESCAMPS O, Tomassini JE, Lin J, Polis AB, et al
    Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
    Atherosclerosis. 2015;240:482-489.
    PubMed     Text format     Abstract available


  65. HARALAMBOS K, Whatley SD, Edwards R, Gingell R, et al
    Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Atherosclerosis. 2015;240:190-196.
    PubMed     Text format     Abstract available


  66. DEROSA G, Romano D, D'Angelo A, Maffioli P, et al
    Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses.
    Atherosclerosis. 2015;239:87-92.
    PubMed     Text format     Abstract available


  67. MEKONNEN G, Corban MT, Hung OY, Eshtehardi P, et al
    Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Atherosclerosis. 2015;239:55-60.
    PubMed     Text format     Abstract available


  68. ALIS R, Sanchis-Gomar F, Risso-Ballester J, Perez-Quilis C, et al
    Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis.
    Atherosclerosis. 2015;239:38-42.
    PubMed     Text format     Abstract available


  69. ODA E
    Cross-sectional and longitudinal associations between serum bilirubin and dyslipidemia in a health screening population.
    Atherosclerosis. 2015;239:31-7.
    PubMed     Text format     Abstract available


  70. HENDRIKS EJ, de Jong PA, van der Graaf Y, Mali WP, et al
    Breast arterial calcifications: a systematic review and meta-analysis of their determinants and their association with cardiovascular events.
    Atherosclerosis. 2015;239:11-20.
    PubMed     Text format     Abstract available


    February 2015
  71. TASKINEN MR, Boren J
    New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Atherosclerosis. 2015;239:483-495.
    PubMed     Text format     Abstract available


  72. KADOYA M, Koyama H, Kurajoh M, Kanzaki A, et al
    Sleep, cardiac autonomic function, and carotid atherosclerosis in patients with cardiovascular risks: HSCAA study.
    Atherosclerosis. 2015;238:409-14.
    PubMed     Text format     Abstract available


  73. GARCIA-SANCHEZ C, Posadas-Romero C, Posadas-Sanchez R, Carreon-Torres E, et al
    Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores.
    Atherosclerosis. 2015;238:250-5.
    PubMed     Text format     Abstract available


  74. SHIMIZU M, Furusyo N, Mitsumoto F, Takayama K, et al
    Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS).
    Atherosclerosis. 2015;238:207-12.
    PubMed     Text format     Abstract available


    January 2015
  75. DONG B, Singh AB, Azhar S, Seidah NG, et al
    High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
    Atherosclerosis. 2015;239:364-374.
    PubMed     Text format     Abstract available


  76. FUTEMA M, Kumari M, Boustred C, Kivimaki M, et al
    Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?
    Atherosclerosis. 2015;239:295-298.
    PubMed     Text format     Abstract available


  77. LEFORT B, Saheb S, Bruckert E, Giraud C, et al
    Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;239:158-162.
    PubMed     Text format     Abstract available


    December 2014
  78. BELL DA, Pang J, Burrows S, Bates TR, et al
    Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience.
    Atherosclerosis. 2014;239:93-100.
    PubMed     Text format     Abstract available


  79. WENG SF, Kai J, Andrew Neil H, Humphries SE, et al
    Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).
    Atherosclerosis. 2014;238:336-343.
    PubMed     Text format     Abstract available


    November 2014
  80. HIDDINK L, Dallinga-Thie GM, Hovingh GK, de Visser MC, et al
    Annexin A5 haplotypes in familial hypercholesterolemia: Lack of association with carotid intima-media thickness and cardiovascular disease risk.
    Atherosclerosis. 2014;238:195-200.
    PubMed     Text format     Abstract available


  81. LAHTINEN AM, Havulinna AS, Jula A, Salomaa V, et al
    Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population.
    Atherosclerosis. 2014;238:64-69.
    PubMed     Text format     Abstract available


  82. JANNES CE, Santos RD, de Souza Silva PR, Turolla L, et al
    Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects.
    Atherosclerosis. 2014;238:101-107.
    PubMed     Text format     Abstract available


  83. FADINI GP, Simoni F, Cappellari R, Vitturi N, et al
    Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2014;237:805-808.
    PubMed     Text format     Abstract available


    October 2014
  84. MOLLAKI V, Progias P, Drogari E
    Familial Hypercholesterolemia in Greek children and their families: Genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum.
    Atherosclerosis. 2014;237:798-804.
    PubMed     Text format     Abstract available


  85. ZENG RX, Li XL, Zhang MZ, Guo YL, et al
    Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes.
    Atherosclerosis. 2014;237:536-543.
    PubMed     Text format     Abstract available


    September 2014
  86. SKOUMAS J, Liontou C, Chrysohoou C, Masoura C, et al
    Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
    Atherosclerosis. 2014;237:140-145.
    PubMed     Text format     Abstract available


  87. FOLSE HJ, Goswami D, Rengarajan B, Budoff M, et al
    Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Atherosclerosis. 2014;236:154-61.
    PubMed     Text format     Abstract available


  88. BOLLI P
    Treatment of dyslipidemia: the problem of reaching the goal.
    Atherosclerosis. 2014;236:142-3.
    PubMed     Text format     Abstract available


    July 2014
  89. LIU JJ, Sum CF, Tavintharan S, Yeoh LY, et al
    Obesity is a determinant of arterial stiffness independent of traditional risk factors in Asians with young-onset type 2 diabetes.
    Atherosclerosis. 2014;236:286-291.
    PubMed     Text format     Abstract available


  90. PRENNER SB, Mulvey CK, Ferguson JF, Rickels MR, et al
    Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.
    Atherosclerosis. 2014;236:244-250.
    PubMed     Text format     Abstract available


    June 2014
  91. JAHAGIRDAR R, Zhang H, Azhar S, Tobin J, et al
    A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
    Atherosclerosis. 2014;236:91-100.
    PubMed     Text format     Abstract available


  92. MABUCHI H, Nohara A, Noguchi T, Kobayashi J, et al
    Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Atherosclerosis. 2014;236:54-61.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: